Articles tagged with Drug Studies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A Phase III trial showed a significant overall survival benefit of 63.9 months with ribociclib, compared to 51.4 months with hormone therapy alone. The estimated six-year survival rate was 44.2% with ribociclib, compared to 32% for placebo.
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.
A new trial run by UCL researchers shows promise in slowing the regrowth of tumors among some bowel cancer patients. The drug adavosertib was found to delay tumour growth by about two months on average and had relatively few side effects, particularly in left-sided/rectal tumours.
A clinical trial found that over half of patients with non-small cell lung cancer (NSCLC) with a HER2 gene mutation had their tumors stop growing or shrink after treatment with trastuzumab deruxtecan. The drug showed durable responses in 54.9% of patients, with median survival period of 17.8 months.
Researchers from University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine found that combining long-term injectable medications with psychosocial intervention improves adherence and symptoms in patients with bipolar disorder. The study enrolled 30 people with bipolar disorder who had adherenc...
Using surrogate endpoints to measure new drug efficacy can reduce trial costs and complexity but also makes decisions more challenging for patients and clinicians. Experts call for more selective use of surrogate endpoints in chronic diseases with patient-relevant outcomes.
A two-dose Ebola vaccine regimen has been found to be safe, well-tolerated, and produce a strong immune response in people over 1 year old. The study also supports the use of this regimen for Ebola virus disease prevention in children and adults.
Researchers have identified nine FDA-approved drugs that can effectively suppress SARS-CoV-2 replication in human cells. These compounds have been shown to be safe in humans and could potentially provide an alternative treatment for COVID-19 patients.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Researchers found that certain species of gut bacteria accumulate human drugs, altering their types, activity, and metabolism. This can change the effectiveness of the drug both directly and indirectly, affecting side effects.
The GPGD database contains records for 903 herb species, including DNA barcodes, organelle genomes, and whole genomes. It provides essential resources for species identification, biosynthetic pathway decomposition, and molecular-assisted breeding analysis.
The first-in-human clinical trial for a vaccine to treat opioid use disorders has enrolled its first patients. The vaccine, developed by researchers at the University of Minnesota Medical School, aims to selectively prevent the euphoric and toxic effects of oxycodone.
A modified chemotherapy regimen for Burkitt lymphoma has been developed, combining CODOX-M and IVAC with rituximab, to reduce toxicity and improve survival rates. The study found a higher overall survival rate and lower frequency of severe side effects compared to standard regimens.
Researchers from Florida Atlantic University's Schmidt College of Medicine review recent randomized trials, concluding that hydroxychloroquine poses significant harm in treating COVID-19. The study suggests a halt on prescribing the medication, recommending vaccination and masking instead as effective public health strategies.
The MASTER DAPT trial found that one month of dual antiplatelet therapy preserves ischemic benefits and reduces bleeding risk in high bleeding risk patients. Abbreviated DAPT was noninferior to standard DAPT in terms of net adverse clinical events, but superior in reducing major or clinically relevant nonmajor bleeding.
Researchers reviewed 79 studies on neurocognitive impairments and brain abnormalities associated with nonfatal opioid overdoses in humans. The findings suggest a link between overdose, cognitive impairment, and brain changes, which could influence attention span, memory, and executive function.
The FIGARO-DKD trial found that finerenone improved cardiovascular outcomes in patients with mild-to-moderate kidney disease and type 2 diabetes. Finerenone reduced the risk of cardiovascular morbidity and mortality by 13%, largely driven by a 29% reduction in hospitalization for heart failure.
A combination therapy of aspirin, statins, and at least two blood pressure medications cuts the risk of fatal cardiovascular disease by over half. The treatment strategy, known as a polypill, is consistent in benefits across different blood pressure levels, cholesterol levels, and diabetes status.
A new strategy using a pill containing four medicines has been shown to be more effective in getting blood pressure under control compared to traditional monotherapy, with 80% of participants achieving blood pressure control within 12 weeks.
A large clinical trial has identified empagliflozin as a treatment option for heart failure with preserved ejection fraction, reducing risk of hospitalization or death by 21 percent. The drug also showed fewer symptoms and mild side effects.
A clinical trial has shown that a triple combination therapy consisting of elexacaftor, tezacaftor, and ivacaftor is safe and effective in cystic fibrosis patients with rare genetic defects. The treatment improves CFTR function, lung function, and quality of life in these patients.
A Phase 2 trial found that combining cisplatin, gemcitabine, and berzosertib did not prolong progression-free survival in patients with urothelial cancer. The study suggests that berzosertib may have a negative impact on bone marrow, leading to reduced white blood cells and platelets.
A new TB prevention regimen for HIV-positive individuals has shown promising results, with 90.4% completing the three-month course compared to 50.5% of those on a six-month daily treatment. The study suggests that this shorter approach is as safe and effective as the standard treatment.
A randomized trial found that a shorter course of rifapentine-isoniazid therapy resulted in significantly higher treatment completion rates compared to a longer daily course. The findings suggest that this regimens can be more effective for preventing tuberculosis disease in individuals with HIV, particularly in high-transmission areas.
Researchers at Purdue University and Houston Methodist have developed a novel TB vaccine formulation that enhances T cell responses to combat tuberculosis. The new vaccine uses autophagy-mediated antigen presentation, showing promising results in improving immune response.
Researchers have identified several drug contenders that can block or reduce SARS-CoV2 infection in cells, including lactoferrin and MEK-inhibitors. These findings suggest potential efficacy against COVID-19 variants, with ongoing clinical trials to examine their ability to reduce viral loads and inflammation.
A nationwide study found that US health systems used COVID-19 treatments dexamethasone and remdesivir variably, with dexamethasone possibly underused in severe cases. The use of these drugs peaked in mid-2020 but fell to lower rates by late February 2021.
Recent studies demonstrate the applications of LC-MS in characterizing Traditional Chinese Medicine formulations, real-time drug measurement, and bioactive compounds from Osmanthus fragrans. These techniques offer high sensitivity, robustness, and ease of use for quality assessment and characterization.
Black, Hispanic, Indigenous and Asian Americans remain underrepresented in pancreatic cancer clinical trials, despite federal mandates. The lack of diversity hurts patients and science alike, with racial and ethnic minorities accounting for a disproportionate burden of pancreatic cancer cases.
A multicenter randomized trial showed acupuncture improved symptoms of moderate to severe CP/CPPS, with effects lasting over 24 weeks. Acupuncture was more effective than sham therapy in reducing symptoms and improving quality of life for men with chronic prostatitis/chronic pelvic pain syndrome.
Researchers found that four patients with rare angiosarcoma partially or completely responded to treatment with a combination of ipilimumab and nivolumab. Stable disease was maintained by two more patients, with at least one patient experiencing complete tumor disappearance.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
The article considers the ethical issues surrounding enrolling children with neurodevelopmental conditions, such as autism spectrum disorder and fragile X syndrome, in clinical trials. Parents may face difficult decisions about whether to enroll their children due to concerns about potential loss of positive aspects of their condition.
A licensed drug normally used to treat abnormal levels of fatty substances in the blood, fenofibrate, has been shown to significantly reduce SARS-COV-2 infection in human cells in laboratory settings. The reduction of infection was obtained using safe and achievable concentrations of the drug.
Researchers found no evidence of increased suicide risk among patients taking recently developed antiseizure medications. The study suggests that the FDA's blanket warning on anti-seizure medications may not be justified, highlighting concerns about its impact on patient treatment and trial results.
A study examined the association between COVID-19 and prescription medication changes among nursing home residents in Ontario, Canada. The researchers found significant changes in medication prescribing patterns before and after the pandemic onset.
A new study published in DNA Repair shows that hydroxychloroquine exhibits DNA-damaging and mutagenic effects at a clinically achievable dose. The findings suggest the possibility of additional side effects, particularly in patient populations, and emphasize the need for careful risk assessment and informed consent.
A synthetic hinge concept developed by Indiana University School of Medicine Professor Michael A. Weiss and his team could lead to a breakthrough in 'smart' insulin therapy. The invention exploits a natural mechanism that allows the insulin to adjust its activity based on blood glucose levels, which could transform diabetes care.
A new study finds that youth-onset type 2 diabetes increases the risk of developing serious complications by young adulthood. Within 15 years of diagnosis, nearly a third of participants had two or more complications, including heart disease, kidney disease, and eye disease.
A phase 2 study found that riluzole slowed brain metabolic decline and improved cognitive performance in patients with mild Alzheimer's disease. The drug targets glutamate dysregulation thought to contribute to the development of Alzheimer's.
A study found that antibodies produced to fight Covid-19 can trigger platelet activity, leading to fatal blood clots. Researchers developed a lab-based test to replicate this process, and suggest that existing medications may be able to inhibit platelet response.
Analysis of real-world data found that ACE inhibitors and ARBs prevent heart events with equal effectiveness, but ARBs may cause fewer side effects. Patients taking ARBs were 3.3 times more likely to develop angioedema, while those taking ACE inhibitors were 32% more likely to experience a cough.
A multinational observational study compared the safety and efficacy of ARBs and ACE inhibitors, finding no significant differences in cardiovascular outcomes but a lower risk of side effects with ARBs. The study analyzed data from over 3 million patients worldwide and used advanced mathematical techniques to reduce bias.
A study found that lonely older adults are at a higher risk of using high-risk medications. The survey data analysis revealed a significant correlation between loneliness and medication use among adults over 65.
A phase 2 trial of Loncastuximab tesirine demonstrates efficacy in treating relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), with a response rate of 48% among patients. The drug, an antibody-drug complex targeting CD19, provides a novel mechanism of action for this patient population.
A new dietary supplement, K.Vita, has been shown to reduce seizures in children and adults with drug-resistant epilepsy, with a mean 50% reduction in seizures or paroxysmal events. The study found that the supplement was well-tolerated and palatable, with fewer than 10% of participants producing significant ketones.
A new clinical trial aims to test a personalized treatment for severe asthma targeting a specific mutation found disproportionately in people of color. The trial, led by Boston Children's Hospital, will test dupilumab, an existing drug that blocks the mutated IL-4 receptor, in patients with and without the mutation.
Researchers analyzed 1.95 million family units, finding a low overall rate of misattributed paternity (1.7%) with rates closer to 1% in recent decades. The study's findings suggest that misattributed paternity is unlikely to have significant effects on hereditary condition studies.
A novel method predicts COVID-19 clinical trial success rates by analyzing features from clinical trial reports, including keywords and drug information. The model achieved high accuracy in predicting trial status, indicating a potential tool for optimizing research efforts and reducing costs.
A study by Cleveland Clinic found that combining a weight management program with FDA-approved anti-obesity medications leads to significant weight loss among adults with obesity. The research showed that participants who had access to the medications averaged -7.7% weight loss at 12 months, compared to -4.2% in those without medication.
Researchers at the University of Waterloo are using mathematical models to simulate COVID-19 infections and test drug efficacy. The models allow for virtual trials, helping narrow down effective treatments before clinical trials begin.
The global Phase 2/3 study with opaganib in patients hospitalized with severe COVID-19 pneumonia has completed patient treatment and follow-up. The company expects to report top-line results in the coming weeks, which will determine the efficacy of opaganib in treating COVID-19.
The DAPA-CKD trial found that dapagliflozin significantly reduced kidney function decline, cardiovascular events, and mortality rates in patients with stage 4 chronic kidney disease. The study also showed similar safety profiles for dapagliflozin and placebo in this patient population.
A study found that adolescent girls and young women in Africa consistently used daily oral PrEP and monthly dapivirine vaginal ring to prevent HIV. The results exceeded expectations, with 97% of participants using the products, indicating high acceptability and adherence.
A study found that high-dose buprenorphine administered in emergency departments is safe and tolerable, providing extended withdrawal relief and helping patients navigate barriers to follow-up care. The therapy may enhance opioid use disorder treatment outcomes, particularly for vulnerable populations.
A Vanderbilt University Medical Center study found that benzodiazepines and non-benzodiazepine hypnotics (z-drugs) significantly increase the risk of death when used in combination with opioid pain medications. The risk is particularly high for those taking benzodiazepines, which had a 221% increased risk of death.
A new study published in the North American Menopause Society's journal Menopause found that a plant-based diet rich in soy reduces moderate-to-severe hot flashes by 84%, with nearly 60% of women becoming free of these symptoms. The study also showed improvements in sexual symptoms, mood, and overall energy.
Researchers found a 40% objective response rate for patients with advanced malignant peritoneal mesothelioma treated with atezolizumab and bevacizumab. The treatment was well-tolerated, with improved progression-free and overall survival rates compared to standard chemotherapy.
A new trial found that remdesivir and hydroxychloroquine have no impact on viral clearance in hospitalized COVID-19 patients. Despite not affecting mortality, the treatment groups showed a decrease in SARS-CoV-2 load within the first week.
A study by the University of Nottingham found that managing medications at the end of life can be a significant 'work' task for families. The research highlights the need for healthcare professionals to provide tailored support and for simplifying Health and Social Care services to make them more navigable.